Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

27 January 2020

Drugs giants must help to solve the antibiotics crisis

Commenting in the Times, Tim Jinks, head of the drug-resistant infections priority programme at the Wellcome Trust, highlights the need for change in how we value and reimburse antibiotics.

Direct links

Read the full article

Tim Jinks looks at the prospects for new antibiotic treatments given today's fragile antibiotic market:

The broken global market for antibiotics and the failure of governments to give it the overhaul it badly needs has meant that many big pharmaceutical companies have either left the field altogether or disinvested.

The commentary compares the 2020 AMR Benchmark to reports issued previously by the World Health Organization, which reached similar conclusions about the overall lack of private investment and innovation in antibiotic development. 

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved